<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="118793">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01556490</url>
  </required_header>
  <id_info>
    <org_study_id>TS-103</org_study_id>
    <nct_id>NCT01556490</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer</brief_title>
  <acronym>STOP-HCC</acronym>
  <official_title>A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients With Unresectable Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable
      hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All
      patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From time of randomization up to 45 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard-of-care sorafenib, with no added therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard-of-care sorafenib plus TheraSphere</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TheraSphere</intervention_name>
    <description>Yttrium 90 microspheres</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent prior to any study-related evaluation

          -  Male or female patients over 18 years of age

          -  Unresectable HCC confirmed by histology or by non-invasive AASLD criteria

          -  Measurable disease defined as at least one uni-dimensional measurable lesion by CT or
             MRI according to RECIST 1.1

          -  Child Pugh score ≤ 7 points

          -  ECOG Performance Status score of ≤ 1

          -  Life expectancy of 12 weeks or more

          -  Eligible to receive standard-of-care sorafenib

          -  Platelet count of &gt; 50 x 10⁹ or &gt; 50% prothrombin activity

          -  Hemoglobin ≥ 8.5 g/dL

          -  Bilirubin ≤ 2.5 mg/dL

          -  ALT and AST&lt; 5 X upper limit of normal

          -  Amylase and lipase ≤ 2X upper limit of normal

          -  Serum creatinine ≤ 1.5 X upper limit of normal

          -  INR &lt; 2.0

        Exclusion Criteria:

          -  Main portal vein thrombosis

          -  Eligible for curative treatment (ablation or transplantation)

          -  History of previous or concurrent cancer other than HCC unless treated curatively 5
             or more years prior to entry

          -  Confirmed presence of extra-hepatic disease except lung nodules and mesenteric or
             portal lymph nodes ≤ 2.0 cm each

          -  Risk of hepatic or renal failure

          -  Tumor replacement &gt; 70% of total liver volume based on visual estimation by
             investigator OR tumor replacement &gt;50% of total liver volume in the presence of
             albumin &lt;3 mg/dL

          -  History of severe allergy or intolerance to contrast agents, narcotics sedatives or
             atropine that cannot be managed medically

          -  Contraindications to angiography and selective visceral catheterization

          -  Known contraindications to sorafenib including allergic reaction, pill-swallowing
             difficulty, evidence of severe or systemic diseases, uncontrolled hypertension or
             history of cardiac arrhythmias (requiring anti-arrhythmic therapy or pace maker),
             congestive heart failure . New York Heart Association class 2, myocardial infarct
             within 6 months, prolonged QT/QTc &gt;450ms, or laboratory finding that in the view of
             the investigator makes it undesirable for the patient to participate in the trial,
             significant GI bleed within 30 days, metastatic brain disease, renal failure
             requiring dialysis

          -  Taking any of the following: Rifampicin, St. John's Wort, phenytoin, carbamazepine,
             phenobarbital, dexamethasone

          -  Taking any other systemic anticancer agent (docetaxel, doxorubicin, irinotecan)

          -  Taking any substrate agents for CYP 2B6 (bupropion, cyclophosphamide, efavirenz,
             ifosfamide, methadone, paclitaxel, amodiaquine, repaglinide)

          -  Taking any UGT 1A1 and UGT 1A9 substrates (e.g. irinotecan)

          -  Taking P-Gp substrates (e.g. Digoxin)

          -  Prior liver resection must have taken &gt;2 months prior to randomization

          -  Treatment with other locoregional therapies (other than study treatment) has not been
             planned for the duration of the clinical study period

          -  Prior external beam radiation treatment to the liver or abdomen

          -  Prior yttrium-90 microsphere treatment to the liver

          -  Prior treatment with transarterial chemoembolization (TACE) or bland embolization &gt;2
             months prior to randomization and must have been applied to a treatment field and/or
             lobe not targeted for treatment under this protocol

          -  Anti-cancer therapy or any treatment with an investigational agent within 30 days
             prior to randomization

          -  Adverse effects due to prior therapy unresolved at randomization

          -  Prior systemic treatment for the treatment of HCC, including sorafenib

          -  Evidence of pulmonary insufficiency or clinically evident chronic obstructive
             pulmonary disease

          -  Intervention for, or compromise of, the Ampulla of Vater

          -  Clinically evident ascites (trace ascites on imaging is acceptable)

          -  Pregnancy or breast feeding

          -  Women of child-bearing potential must have a negative serum pregnancy test within 14
             days prior to randomization

          -  Disease or condition that would preclude safe use of TheraSphere, including
             concurrent dialysis treatment, or unresolved serious infections including patients
             who are known HIV positive

          -  Participation in concurrent clinical trials evaluating treatment intervention(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Riad Salem, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Radiology Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurie Graham</last_name>
    <phone>(+1) 910 350 3632</phone>
    <email>Laurie.Graham@Chiltern.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carrie Hansen</last_name>
    <phone>(+1) 760 473 103</phone>
    <email>carrie.hansen@Chiltern.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>George Washington University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlene del Castillo</last_name>
      <phone>312-695-1409</phone>
      <email>carlene.castillo@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Laura Kulik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reena Mehta</last_name>
      <phone>312-563-4238</phone>
      <email>reena_mehta@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Sheila Eswaran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Northshore Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Vanderloo</last_name>
      <phone>847-570-4208</phone>
      <email>avanderloo@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Claus Fimmel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Schlegel, RN</last_name>
      <phone>502-629-3383</phone>
      <email>melissa.schlegel@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Martin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colette Zack</last_name>
      <phone>313-576-9385</phone>
      <email>zackc@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Courtney Wolf</last_name>
      <phone>313-576-9376</phone>
      <email>wolfc@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Philip Philip, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Mary's Healthcare</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Estkowski</last_name>
      <phone>616-685-5156</phone>
      <email>estkowk@mercyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Matthew Tiede, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pickett</last_name>
      <phone>507-284-0586</phone>
      <email>pickett.jennifer@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Lewis Roberts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Stern</last_name>
      <phone>212-746-9748</phone>
      <email>jas2071@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Adam Talenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miami Valley Hospital</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Kibler</last_name>
      <phone>937-208-2872</phone>
      <email>nkibler@premierhealth.com</email>
    </contact>
    <investigator>
      <last_name>Shannon Kauffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Legacy Meridian Park Medical Center</name>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <zip>97062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Pedano, RTR,CVR,RA</last_name>
      <phone>215-955-4129</phone>
      <email>nancy.pedano@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Colette Shaw, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Lamson</last_name>
      <phone>412-864-3292</phone>
      <email>lamsons@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>David Gellar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Marks Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Turpin</last_name>
      <phone>801-269-0231</phone>
      <email>melinda.turpin@mountainstarhealth.com</email>
    </contact>
    <investigator>
      <last_name>James Carlisle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sentra Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela M Bowman, RN BSN</last_name>
      <phone>757-388-2533</phone>
      <email>ambowman@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Harlan Vingan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Obsy Tadesse</last_name>
      <phone>206-288-6439</phone>
      <email>otadesse@seattle.ca.org</email>
    </contact>
    <investigator>
      <last_name>Siddharth Padia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William P Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Wertz</last_name>
      <phone>0032 4 366 7439</phone>
      <email>swertz@chu.ulg.ac.be</email>
    </contact>
    <investigator>
      <last_name>Jean Delwaide</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hspital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne McGoey</last_name>
      <phone>(780) 407 6912</phone>
      <email>joanne.mcgoey@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Richard Owen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Punzalan</last_name>
      <phone>604 875 4111</phone>
      <phone_ext>21726</phone_ext>
      <email>marie.punzalan@vch.ca</email>
    </contact>
    <investigator>
      <last_name>David Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lou Magdale</last_name>
      <phone>416 593 0501</phone>
      <phone_ext>6639</phone_ext>
      <email>lou.magdale@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Robert Beecroft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre / Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayat Salman</last_name>
      <phone>(514) 934-1934</phone>
      <phone_ext>36237</phone_ext>
      <email>Ayat.Salman@MUHC.MCGILL.CA</email>
    </contact>
    <investigator>
      <last_name>David Valenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <zip>852</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koh Jane</last_name>
      <phone>(852)2632 1142</phone>
      <email>Jane@clo.cuhk.edu.hk</email>
    </contact>
    <investigator>
      <last_name>Simon Yu, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Hôpital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ony Ranaivoson</last_name>
      <phone>0033 149 81 21 11</phone>
      <phone_ext>16313</phone_ext>
      <email>ony.ranaivoson@hmn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Costentin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nora Perrot</last_name>
      <phone>0033(0)3.80.28.12.66</phone>
      <email>nora.perrot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Hillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Marlu</last_name>
      <phone>00 33 4 76 76 61 50</phone>
      <email>AMarlu@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Thomas Decaens</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon-Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Metral</last_name>
      <phone>00 33 4.26 55 68 44</phone>
      <email>Pierre.METRAL@lyon.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Frank Pilleul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone CHU</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Séverine Saurier</last_name>
      <email>severine.saurier@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Rene Gerolami</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perrin Rocher</last_name>
      <phone>0033 467 33 75 45</phone>
      <email>p-rocher@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>George Philippe Pageaux, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helene Auble</last_name>
      <phone>0033 240 08 31 52</phone>
      <email>Helene.AUBLE@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Archambeaud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Viano</last_name>
      <phone>0033 4 92 03 90 01</phone>
      <email>mourgues.s@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Patrick Chevallier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque, CHU Bordeaux</name>
      <address>
        <city>Pessac Cedex</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie Cavillon</last_name>
      <phone>00 33 5.57.65.61.72</phone>
      <email>elodie.cavillon@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Baptiste Hiriart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia Rouleau</last_name>
      <phone>00 33 5 49 44 30 44</phone>
      <phone_ext>46 036</phone_ext>
      <email>Laetitia.ROULEAU@chu-poitiers.fr</email>
    </contact>
    <investigator>
      <last_name>Christine Silvain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims Cedex</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Feron</last_name>
      <phone>00 33 3.26.83.26.31</phone>
      <email>tferon@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandra Heurgue, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes Cedex</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurelie Sauvanet</last_name>
      <phone>02 99 25 32 54</phone>
      <email>a.sauvanet@rennes.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marc Pracht, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Lagarde</last_name>
      <phone>335 61 77 95 98</phone>
      <email>lagarde.b@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Marie Peron</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiline Lapre</last_name>
      <phone>0033 383153355</phone>
      <email>emiline.lapre@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Bronowicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Coralie Gasc</last_name>
      <phone>00 33 1 42 11 54 09</phone>
      <email>coralie.gasc@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Debaere, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gonzalez-Carmona</last_name>
      <phone>0049 228 287 15507</phone>
      <email>Maria.Gonzalez-Carmona@ukb.uni-bonn.de</email>
    </contact>
    <investigator>
      <last_name>Christian Strassburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Van Ngo</last_name>
      <phone>0049 201 723 85013</phone>
      <email>hong.vanngo@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Stefan Müller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Therese Raatschen</last_name>
      <phone>0049 511 532-5791</phone>
      <email>Raatschen.Marietheres@mh-hannover.de</email>
    </contact>
    <investigator>
      <last_name>Arndt Vogel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero -Universitaria di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Scandellari</last_name>
      <phone>0039 051 214 2647</phone>
      <phone_ext>2307</phone_ext>
      <email>&quot;elena.scandellari@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Rita Golfieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KyongHee Shin</last_name>
      <phone>82-2-2258-1456</phone>
      <email>drange366@naver.com</email>
    </contact>
    <investigator>
      <last_name>Ho Jong Chun</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anyes Kyung</last_name>
      <phone>82-2-2072-0385</phone>
      <email>anyes1118@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Yoon Jun Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pyeong-Eui Kim</last_name>
      <phone>82-10-4799-9982</phone>
      <email>irene729@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Jong Yun Won</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoyan Wang</last_name>
      <phone>6567723443</phone>
      <email>xiaoyan_wang@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Stephen Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UDIAT Corporacio Parc Tauli</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Criado-Paredes</last_name>
      <phone>0034 93 723 10 10</phone>
      <phone_ext>21147</phone_ext>
      <email>ECRIADO@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Eva Criado-Paredes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Carrera</last_name>
      <phone>0034 913368263</phone>
      <email>cristina.carrera.hryc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Guillen-Ponce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptal Universitario Central de Asturias (nuevo HUCA)</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Ferrusquía</last_name>
      <phone>0034 985 108 000</phone>
      <phone_ext>38667</phone_ext>
      <email>ferruzkiaz@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Maria Varela, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northern Centre Cancer Care</name>
      <address>
        <city>New Castle Upon Tyne</city>
        <state>Newcastle Upon Tyne</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Stoddart</last_name>
      <phone>0191 213 8438</phone>
      <email>Jonathan.Stoddart@nuth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kate Sumpter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Surrey Country Hospital</name>
      <address>
        <city>Guildford</city>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ceri Jamieson</last_name>
      <phone>01483 406612</phone>
    </contact>
    <investigator>
      <last_name>Tony Dhillon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L69 3GA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Palmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Cancer Institute</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Hamilton</last_name>
      <email>sarahamilton@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Tim Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital;</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jozer Calara</last_name>
      <phone>0203 2997666</phone>
      <email>jozer.calara@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Paul Ross</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weston Park Hospital, Sheffield</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Redfearn</last_name>
      <phone>0044 114 226 51 60</phone>
      <email>a.redfearn@sheffield.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Suzanne Darby</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.theraspheretrials.com/stop-hcc</url>
    <description>Trial-specifc website</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 7, 2017</lastchanged_date>
  <firstreceived_date>March 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
